A nurse is caring for a client with acute myeloid leukemia (AML) who has developed tumor lysis syndrome following chemotherapy initiation. The client's laboratory results show: potassium 7.2 mEq/L, phosphorus 9.0 mg/dL, calcium 6.8 mg/dL, and uric acid 14.0 mg/dL. Which nursing intervention should be the priority?

Tumor lysis syndrome is a life-threatening oncological emergency. The priority intervention is cardiac monitoring for hyperkalemia (K+ 7.2 mEq/L), as severe hyperkalemia can cause fatal cardiac arrhythmias. Other interventions like fluid intake or phosphate binders are important but secondary to managing the immediate cardiac risk.

Understanding the Priority in Tumor Lysis Syndrome

The client’s laboratory values reveal the classic metabolic derangements of tumor lysis syndrome (TLS): severe hyperkalemia (potassium 7.2 mEq/L), hyperphosphatemia (phosphorus 9.0 mg/dL), hypocalcemia (calcium 6.8 mg/dL), and hyperuricemia (uric acid 14.0 mg/dL). TLS is an oncologic emergency characterized by severe metabolic derangements resulting from rapid tumor cell breakdown, which releases massive amounts of intracellular contents into the bloodstream ^[1]. When prioritizing nursing interventions, the immediate threat to life is the most critical consideration.

A potassium level of 7.2 mEq/L constitutes a life-threatening emergency due to its direct effect on cardiac electrophysiology. Hyperkalemia-induced arrhythmias can be rapidly fatal, and prompt recognition and treatment is vital ^[2]. The elevated potassium alters the resting membrane potential of cardiac cells, leading to a progression of ECG changes from peaked T-waves to widened QRS complexes, and ultimately to ventricular fibrillation or asystole. The simulation-based literature emphasizes that severe hyperkalemia in TLS, if untreated, may lead to renal failure, arrhythmias, or multi-organ failure ^[2]. Therefore, preparing for immediate cardiac monitoring and potential emergency interventions—such as administering intravenous calcium gluconate to stabilize the cardiac membrane (which is distinct from correcting the potassium level itself) and initiating therapies to shift potassium—is the absolute priority.

While the other options address real and significant TLS abnormalities, they do not target the most immediate threat. Administering calcium gluconate (Option 1) is a critical component of treating hyperkalemia’s cardiac effects, but the stated goal of "correcting hypocalcemia" is a secondary concern. The hypocalcemia in TLS is a direct consequence of hyperphosphatemia, as calcium binds to the excess phosphorus; the priority is to manage the life-threatening hyperkalemia, and calcium gluconate given for cardiac membrane stabilization serves that purpose, not primarily to normalize the serum calcium. Increasing fluid intake (Option 2) is essential for promoting uric acid excretion and preventing acute kidney injury, a known complication of TLS ^[1], but it does not provide immediate protection against a fatal arrhythmia. Administering phosphate binders (Option 4) is a longer-term strategy to lower phosphorus levels, which will secondarily help correct hypocalcemia, but it has no immediate impact on the hyperkalemia that poses a clear and present danger. The clinical reasoning must follow the "ABC" (Airway, Breathing, Circulation) framework, where a potassium-induced cardiac conduction defect is a direct threat to circulation.